TAK-771

Phase 3

TAKEDA PHARMACEUTICAL CO LTD (TAK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

2mo

TAKPDUFA$60.2B

Phase 3

FDA PDUFA Date TAK-721 (priority)

TAK-771• Primary Immunodeficiency Diseases (PID)

Nov 10Confirmed

SEC

00%

Competitive Landscape

0 competitors in Primary Immunodeficiency Diseases (PID)

View Full Landscape

Drug Information

Target Indication

Primary Immunodeficiency Diseases (PID)

Clinical Trial

NCT05513586

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TAK

TAKEDA PHARMACEUTICAL CO LTD

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

REPLAGALPhase 3

Fabry Disease

Alogliptin and pioglitazonePhase 3

Type 2 Diabetes Mellitus

HYQVIAPhase 3

Primary Immunodeficiency Diseases (PID)

IGSC 20% infusionPhase 3

Primary Immunodeficiency Disease

Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3

Hypertension

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts